Reducing PTSD symptoms in first responders and healthcare workers

Reducing PTSD Symptoms in First Responders and Frontline Healthcare Workers Through Trauma-focused Treatment in Employee Assistance Programs

Not applicable Interventional University of Michigan · NCT05751473

This study tests if a new talk therapy for PTSD can help first responders and healthcare workers feel better than the usual support they get.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment410 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Michigan Academic / other
Locations12 sites (San Diego, California and 11 other locations)
Trial IDNCT05751473 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of a brief talk therapy treatment called Prolonged Exposure for Primary Care (PE-PC) in reducing PTSD symptoms among first responders and frontline healthcare workers. Participants will receive this treatment through Employee Assistance Programs (EAPs) and will be compared to those receiving standard EAP treatment. The central hypothesis is that PE-PC will lead to greater reductions in PTSD symptoms and improved functioning compared to usual care.

Who should consider this trial

Good fit: Ideal candidates include employees of organizations served by participating EAPs who have a confirmed PTSD diagnosis and stable psychotropic medication for at least four weeks.

Not a fit: Patients with severe cognitive impairment, high suicide risk, or active psychosis may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate PTSD symptoms in first responders and healthcare workers, improving their overall mental health and job performance.

How similar studies have performed: Previous studies have shown promise in using similar therapeutic approaches for PTSD, indicating potential for success in this trial.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Are employees at an orginization served by a participating EAP
* Have a Post-Traumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PCL-5) score ≥33
* Have had psychotropic medication stability for at least 4 weeks

Inclusion criteria for the qualitative portion of the study:

\- Enrolled into the randomized clinical trial and were a treatment responder or were a treatment non-responder

Exclusion Criteria:

* Severe cognitive impairment that in the judgment of the investigators makes it unlikely that the participant can adhere to the study regimen (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment)
* High risk of suicide (defined as meeting criteria for Action Step 3 on the Participant Suicide Risk Screening form: found in protocol)
* Need for detoxification
* Active psychosis or unmanaged bipolar disorder, as measured by items 12 and 13 of the cross cutting assessment
* Currently engagement in a trauma-focused behavioral treatment (such as Prolonged Exposure or Cognitive Processing Therapy).
* Patients who do not speak English will be excluded for logistical reasons.

Where this trial is running

San Diego, California and 11 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Post Traumatic Stress DisorderEmployee Assistance ProgramsFrontline Healthcare WorkersProlonged Exposure for Primary CareFirst Responders
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.